Advertisement
News
Advertisement

Foundation Venture Capital Group Invests in Start-Up Company Developing Blood Test to Determine Risk and Diagnose Alzheimer's Disease

Fri, 05/14/2010 - 9:37am
Bio-Medicine.Org

NEW BRUNSWICK, N.J., May 14 /PRNewswire-USNewswire/ -- As many as 5.3 million Americans, and 35 million people worldwide, are living with Alzheimer's disease (AD), a devastating neurodegenerative illness characterized by memory loss, cognitive decline and widespread destruction of neurons in the brain.  Today, there is no definitive diagnosis for the disease, and no treatment to cure it.

AD is the most common form of dementia and, with our aging population, the number of people who will develop the disease is expected to increase dramatically in the future.  

With Foundation Venture Capital Group, LLC's, latest investment, James M. Golubieski, president, is hoping to help to lower those numbers dramatically.  That's why the company has made an initial investment of $175,000, which can go up to $500,000 pending completion of certain milestones, to Durin Technologies, Inc., a start-up company developing a test that requires only a drop of blood to diagnose the disease.

"My research centers on the fact that autoantibodies are involved in the degenerative mechanism of AD," explained Robert Nagele, PhD, founder of Durin Technologies and a researcher at the Institute for Successful Aging at the UMDNJ-School of Osteopathic Medicine in Stratford, NJ.

Dr. Nagele noted that the concept is gaining support in the scientific community and a number of pharmaceutical companies are seriously looking into it to help diagnose, and later treat, AD.

"We are hopeful that Dr. Nagele's research will help to fill an unmet need in the diagnostic and pharmaceutical industries

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading